AngioDynamics Announces Humana Medicare Advantage Coverage Polic
AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.
How this was made
The 30-second read
Why it matters
The policy expands reimbursement, likely improving sales outlook and investor sentiment.
Market read
First‑report coverage expansion for a niche cancer therapy, offering a fresh catalyst for the stock.
What to watch
Potential delays in provider adoption and competition from alternative ablation technologies.
Background
AngioDynamics announced a new Humana Medicare Advantage policy covering its NanoKnife IRE system for specific cancer indications.
Ticker impact
Humana added Medicare Advantage coverage for AngioDynamics' NanoKnife IRE therapy, expanding reimbursement for prostate and liver cancer patients.
likely upward as investors price in higher utilization and revenue potential
Reimbursement expansion is a material catalyst for a medical‑technology firm; similar past coverage updates have lifted stock prices.
Market effects
May signal broader payer acceptance of IRE technology, benefiting similar minimally invasive oncology devices.
U.S. Medicare Advantage market sees increased utilization of NanoKnife, modest impact on regional healthcare spend.
Limited to U.S. payer landscape; minimal direct effect on global markets.
Counterpoint
Coverage may be limited in scope and reimbursement rates could be modest, dampening revenue upside.
Key entities
- companyAngioDynamics, Inc.
Medical‑technology firm developing the NanoKnife IRE system.
- companyHumana Inc.
Large Medicare Advantage insurer implementing the new coverage policy.
